Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Internal Medicine
•
Hematology
How would you treat an elderly patient with DLBCL with only brain and unilateral testicular involvement?
Related Questions
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where BV-AVD may still be preferred?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
What is the optimal choice of therapy for a patient with Hodgkin variant of Richter's transformation from underlying CLL/SLL?
How would you manage a patient with symptomatic low grade leukemic NHL w/o a clear diagnosis of either FL or MZL?
Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP similar to R-miniCHOP?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
